Like many other countries in Africa, Malawi is preparing to revise its policies for prevention of mother-to-child transmission (PMTCT) of HIV and for antiretroviral therapy (ART) in response to WHO's 2010 guidelines.
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In HIV-infected pregnant women ART use is recommended when CD4 cell counts are 350 cells per μL or less, irrespective of WHO clinical stage, or in women with disease in clinical stage 3 or 4. For pregnant women with CD4 cell counts higher than 350 cells per μL or with disease at clinical stage 1 or 2 who do not yet need ART for their own health, WHO proposes two time-limited options for antiretroviral prophylaxis (table) . The Ministry of Health in Malawi chose to use a regimen of tenofovir, lamuvidine, and efavirenz in these women. This regimen is simple, it avoids zidovudine-induced side-eff ects, particularly anaemia, which is a common feature of pregnancy in Malawi, and it will be used as the fi rst-line regimen in adolescents and adults. The logistics of delivery will be improved, the risks of running out of stocks lessened, the need for multiple guidelines and training eliminated, and the likelihood of successful implementation increased. Moreover, the proposed regimen is available in a fi xed-dose combination of one tablet per day, can be safely used with antituberculosis drugs, is eff ective against hepatitis B virus, and can be used without routine laboratory monitoring of toxic eff ects. 9 We propose to off er all HIV-infected pregnant women lifelong ART. This approach is not completely new, but rather is a more feasible alternative to WHO's proposed option B, which we call option B+. The proposed change is akin to the test and treat mathematical model elucidated by Granich and colleagues. 10 In view of the regimen's good safety profi le, the diffi culties involved in expansion of CD4 cell count testing, and the urgent need to increase the coverage of the PMTCT programme, we argue that waiting 2-3 years for the results of a pilot study would not be ethical. We therefore propose immediate implementation of this approach. If CD4 counts did become more accessible in Malawi, the guidelines could be adapted.
The expansion of the PMTCT programme in Malawi through implementation of option B+ would have various other benefi ts. The total fertility rate in Malawi is high, around 5·6 births per woman, 11 which is unlikely to be much lower in HIV-infected women.
12 Soon after the breastfeeding period (median duration 23 months 13 ) many women become pregnant again. Thus, a stop-start approach to ART administration is almost redundant. Many women present for antenatal care late in pregnancy-an estimated 50% are thought to attend after 28 weeks of gestation-and continuing prophylaxis with antiretroviral drugs would mean that the next pregnancy could be protected from conception. The stopping of ART after cessation of breastfeeding might lead to viral rebound, with the risk of transmission to a sexual partner or fetus being notably raised. Scheduled stopping is also diffi cult to implement, as it requires tapering of doses to prevent drug resistance, owing to the diff erent half-lives of the antiretroviral drugs.
Additionally, the risks of opportunistic disease or death might be raised.
14 Tenofovir and lamuvidine are active against hepatitis B virus; 10-15% of people living with HIV infection in Malawi are also infected with Universal, lifelong ART for HIV-infected pregnant women will achieve maximum coverage and could potentially lead to elimination of paediatric HIV/AIDS.
In women in Zimbabwe even those with CD4 cell counts higher than 350 cells per μL had a risk of death around six times higher than that in non-infected women within 24 months post partum, and early ART could reduce mortality by 50-90%. 16 Prevention of maternal deaths has a striking eff ect on child survival, independent of any eff ect gained from the prevention of HIV transmission.
The risk of developing tuberculosis increases with declining CD4 cell counts, from 500 cells per μL;
17 the majority of pregnant women have CD4 cells counts in this range. Early initiation of ART, therefore, reduces the risk of tuberculosis.
18 Observational cohort studies in the USA and Europe also suggest that the early starting of ART signifi cantly lowers mortality related to HIV infection and AIDS.
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In Malawi, most HIV-infected women starting prophylaxis with zidovudine do so without the CD4 cell count being known. As about 50% of these women will have counts of 350 cells per μL or lower, all receive zidovudine monotherapy de facto. Although there is no evidence that exposure to zidovudine prophylaxis in women with advanced HIV disease increases the risk of drug resistance, this possibility is of concern.
HIV-transmission in couples is an important contributor to overall transmission rates, and the use of ART greatly reduces the risk of HIV-transmission to non-HIVinfected partners.
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HIV status and pregnancy can be confi rmed in virtually all health centres in Malawi that provide maternal health services. The message that triple therapy must be taken for life and on a daily basis from the start is simple. Both these features mean the option B+ policy could be rapidly rolled out to and implemented by all centres.
In the fi rst 3 years of the implementation of the option B+ policy we estimate that ART would be started in 25 000 more pregnant women per year than at present; of note, these women would have required ART at some point, and are merely starting treatment earlier. To hit this target, the number of health facilities providing ART would have to increase from 377 to all 650 with mother and child health services. Current constraints on health systems and human resources will need to be addressed to accommodate additional burdens, such as extended intervals between appointments, task-shifting, and expansion of the health staff .
The chosen ART regimen is more expensive than a regimen of stavudine, lamivudine, and nevirapine (US$176 per person per year 21 vs $65), but we believe that the advantages justify the initial added cost. In addition, drug prices are expected to lower over time, and reductions in the number of infections, morbidity, and mortality in children and adults will contribute to a decline in overall treatment cost. Moreover, the management costs of option B+ are likely to be similar to those for option A or B, since the frequency of follow-up for mothers and infants is similar in all three. A full economic analysis, however, is needed.
Efavirenz is potentially teratogenic in the fi rst trimester, but the risk seems to be lower than previously thought. 22 In the absence of conclusive evidence, women who desire pregnancy could be off ered an alternative ART regimen in which nevirapine replaces efavirenz, until the second trimester of the pregnancy. Other women receiving ART should be off ered contraceptives in line with a comprehensive PMTCT strategy. We recognise that exposure to efavirenz cannot be completely avoided in the fi rst trimester, but this risk seems outweighed by increased coverage and muchreduced overall mortality. Our approach off ers a real opportunity to integrate HIV treatment into mother and child health services and make tangible progress towards achieving the relevant Millennium Development Goals. Option B+ favours women rather than men in terms of ART accessibility, although we feel this inequality is acceptable in view of the policy's potential contribution to the elimination of paediatric HIV infection.
The public health model outlined in this Viewpoint is so far untried and untested, but we are confi dent that it can work. Concerns about the acceptability to the general population of HIV testing and ART when that programme was scaled up in 2004 proved unfounded. Community acceptability for this approach would, however, have to be assessed from the start and human rights would have to be protected at all times. In the meantime, community leaders and health-care workers would have to be careful not to coerce people into being tested. National guidelines clearly state that everyone has the right to decline HIV testing without any consequences. We would expect community members and people living with HIV and AIDS to play important parts in the delivery strategy. We propose that sentinel sites are set up to improve human resources, infrastructure, and monitoring and reporting of drug tolerability. The people who would be responsible for administration of ART should be specifi ed before implementation.
Increasing the uptake of PMTCT linked with access to CD4 cell count testing has been a major challenge. Progress towards the relevant Millennium Development Goals will, therefore, depend on additional strategies to substantially increase PMTCT coverage. We need to bridge the implementation gap with a bold PMTCT public health approach.
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